The deal expands the company’s rare disease portfolio
Source: PMLiVE
You may also like
This common pesticide may be quietly wiping out future...
Macrophage Membrane-Derived Nanoparticles Shows...
Epigenomic Analysis Uncovers New AML Subgroups and...
GSK, Hansoh ADC extends survival in lung cancer study
ARPA-H puts $160M into bespoke drug therapies;...
Bausch + Lomb gives up on glaucoma eye drop hopeful...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.